A new market research report indicates that use of the Cardiolite radiopharmaceutical from Lantheus Medical Imaging of North Billerica, MA, dropped 9% in September compared to the previous year, but the agent still has a double-digit lead in market share.
The report by Arlington Medical Resources of Malvern, PA, compared market-share data among the major radiopharmaceuticals for myocardial perfusion stress testing. The study found that while the number of patients who were administered Cardiolite dropped 9%, the agent maintained a 15% lead over its closest competitor, Myoview from GE Healthcare of Chalfont St. Giles, U.K.
The report also found that the Lexiscan pharmacologic stress agent from Astellas of Deerfield, IL, increased 58.5% from August 2008 to September 2008. Lexiscan was introduced in June 2008 and is used in patients unable to undergo exercise stress testing.
Related Reading
Lantheus scores Premier contract, October 24, 2008
Lantheus to license Bracco's CardioGen PET tracer, September 24, 2008
Definity echo contrast agent lands on FDA drug safety list, September 8, 2008
IBA, Lantheus ink radiopharma deal, July 31, 2008
Lantheus reports data from cardiac PET trial, June 17, 2008
Copyright © 2008 AuntMinnie.com
